Graybug Vision Inc (GRAY) News
Filter GRAY News Items
GRAY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest GRAY News From Around the Web
Below are the latest news stories about Graybug Vision Inc that investors may wish to consider to help them evaluate GRAY as an investment opportunity.
Graybug to Participate in Three Upcoming Medical and Investor ConferencesBALTIMORE, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced its participation in three upcoming medical and investor conferences: Angiogenesis, Exudation, and Degeneration 2022 – Virtual Edition – Veeral Sheth, MD, to present on “Safety and Durability of Intravitreal Sunitinib Malate Depot (GB-102) in Wet Age- |
Graybug Vision Makes Key Hires to Further Build Momentum Behind its PipelineBALTIMORE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced the hiring of six new employees who will enhance Graybug’s Research & Development (R&D), Regulatory Affairs and Program Management capabilities, as the Company further builds momentum behind its pipeline in 2022. “We are at a critical stage in our eff |
Graybug Vision (GRAY) Receives a Hold from Leerink PartnersLeerink Partners analyst Marc Goodman maintained a Hold rating on Graybug Vision (GRAY – Research Report) on December 17 and set a price target of $5.00. The company's shares closed last Wednesday at $2.06, close to its 52-week low of $1.79. According to TipRanks.com, Goodman is a 2-star analyst with an average return of 0.1% and a 42.5% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Intra-Cellular Therapies, and Satsuma Pharmaceuticals. Graybug Vision has an analyst consensus of Hold, with a price target consensus of $4.00, which is a 99.0% upside from current levels. |
We Think Graybug Vision (NASDAQ:GRAY) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Graybug Vision, Inc. (NASDAQ:GRAY) Stake Trimmed by Geode Capital Management LLCGeode Capital Management LLC cut its holdings in shares of Graybug Vision, Inc. (NASDAQ:GRAY) by 43.0% in the second quarter, HoldingsChannel reports. The fund owned 70,382 shares of the companys stock after selling 52,989 shares during the quarter. Geode Capital Management LLCs holdings in Graybug Vision were worth $382,000 as of its most recent SEC [] |
Graybug Vision, Inc. (NASDAQ:GRAY) Stock Position Lifted by Vanguard Group Inc.Vanguard Group Inc. lifted its holdings in Graybug Vision, Inc. (NASDAQ:GRAY) by 80.2% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 430,387 shares of the companys stock after purchasing an additional 191,568 shares during the quarter. Vanguard Group Inc. owned 2.04% of Graybug [] |
Graybug Vision, Inc. to Post FY2021 Earnings of ($1.64) Per Share, Wedbush Forecasts (NASDAQ:GRAY)Graybug Vision, Inc. (NASDAQ:GRAY) – Investment analysts at Wedbush cut their FY2021 earnings per share (EPS) estimates for Graybug Vision in a report issued on Monday, November 15th. Wedbush analyst L. Moussatos now forecasts that the company will post earnings per share of ($1.64) for the year, down from their prior forecast of ($1.57). Wedbush […] |
Graybug Vision to Participate in the Piper Sandler 33rd Annual Virtual Healthcare ConferenceBALTIMORE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will participate in a pre-recorded fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference, which will be available on the conference website beginning at 10 a.m. ET / 7 a.m. PT on November 22, 2021. |
Graybug Vision to Participate in the Piper Sandler 33rd Annual Virtual Healthcare ConferenceBALTIMORE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will participate in a pre-recorded fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference, which will be available on the conference website beginning at 10 a. |
Graybug Vision (NASDAQ:GRAY) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPSGraybug Vision (NASDAQ:GRAY) announced its earnings results on Thursday. The company reported ($0.38) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.37) by ($0.01), MarketWatch Earnings reports. Shares of NASDAQ:GRAY opened at $3.14 on Friday. The company has a 50-day moving average price of $3.43 and a two-hundred day moving average price [] |